Recent 8-K filings for PTN
Highest-materiality recent filing
Palatin Technologies receives NYSE American delisting notice; intends to appeal
- NYSE Regulation determined to delist PTN for failure to comply with stockholders' equity requirements (Sections 1003(a)(i)-(iii)).
- Maximum 18-month compliance plan ended April 10, 2025; Company unable to demonstrate regained compliance.
-
Palatin shareholders elect directors, approve 260,000-share increase to stock plan
All four director nominees elected; Carl Spana and John Prendergast each received over 330,000 withheld votes.
-
Palatin Technologies to transfer stock listing from NYSE American to Nasdaq Capital Market
Voluntary withdrawal from NYSE American; last trade expected on NYSE May 28, 2026.
-
Palatin board adopts annual say-on-pay vote after stockholder advisory approval
Stockholders voted, on advisory basis, to hold say-on-pay vote every year at July 25, 2025 annual meeting.
-
Palatin closes $18.2M public offering, regains NYSE American listing compliance
Closed upsized public offering of 2,795,384 shares/pre-funded warrants and warrants at combined $6.50, gross proceeds $18.2M.
-
Palatin prices $15.8M public offering; NYSE American listing resumes Nov 12
Priced upsized public offering of 2.43M shares at $6.50/unit; gross proceeds ~$15.8M.
-
Palatin earns €5.5M milestone payment from Boehringer Ingelheim in retinal disease collaboration
Achieved research milestone in collaboration with Boehringer Ingelheim, triggering €5.5M ($6.5M) payment to Palatin.
-
Palatin begins OTCQB trading under PTNT after 1-for-50 reverse split; delisted from NYSE American
NYSE American suspended trading and initiated delisting on May 7, 2025, due to low stock price.
-
Palatin signs up to €280M collaboration with Boehringer for retinal disease therapies
€2M upfront, up to €18M near-term milestones, up to €260M in regulatory/commercial milestones plus tiered royalties.
-
Palatin Technologies to effect 1-for-50 reverse stock split on August 11, 2025
Reverse split effective after market on August 11; split-adjusted trading on OTCQB begins August 12.
-
Palatin Technologies announces 1-for-50 reverse stock split effective Aug 8, 2025
Reverse stock split at 1-for-50 ratio effective 5:00 p.m. ET on August 8, 2025.
-
Palatin shareholders approve reverse stock split (1:50-1:100) and increase shares for equity awards
Reverse stock split (1:50-1:100) approved; 12.4M for, 8.2M against. Board to set exact ratio.
-
NYSE American Panel affirms delisting of Palatin Technologies; stock trades on OTCQB
Panel unanimously affirmed delisting under Sections 1003(a) and 1003(f)(v) due to low selling price of common stock.
-
Palatin Technologies delisted from NYSE American; raises $340K in insider private placement
NYSE American commenced delisting proceedings; common stock suspended May 7, 2025. Now trades on OTCQB under PTNT.
-
Palatin Technologies delisted from NYSE American; reduced offering raises only $1.1M
NYSE American suspended trading and commenced delisting proceedings due to low stock price; shares transitioned to OTC Pink under 'PTNT'.
-
Palatin Technologies receives NYSE American delisting notice; intends to appeal
NYSE Regulation determined to delist PTN for failure to comply with stockholders' equity requirements (Sections 1003(a)(i)-(iii)).
-
Palatin reports positive Phase 2 topline results for UC drug PL8177 and obesity combo study
UC Phase 2: Clinical remission 33% PL8177 vs 0% placebo; clinical response 78% vs 33% (p<0.005) after 8 weeks.
-
Palatin enters $6M ATM equity distribution agreement with A.G.P.
At-the-market offering of up to $6.0M of common stock via A.G.P./Alliance Global Partners.
-
Palatin Technologies announces $4.7M equity offering at $1.00/share, private warrants
Gross proceeds ~$4.7M from sale of 2.55M shares at $1.00/share and pre-funded warrants for 2.138M shares.
-
Palatin receives ~$3.4M from warrant exercise; issues new Series C/D warrants
Gross proceeds of ~$3.4M from exercise of 3,907,679 shares at amended price $0.875.
-
Net loss $7.8M ($0.39/share) vs $5.2M a year ago; cash $2.4M at Sep 30, plus $2.5M deferred payment from Vyleesi sale received Nov 2024.
-
NYSE American notified Palatin of non-compliance with Section 1003(a)(iii) requiring stockholders' equity of at least $6M after five consecutive years of losses.
-
Net loss for FY2024 $29.7M ($2.02 per share) vs $24.0M ($2.21) prior year; revenue declined as Vyleesi asset sold.
-
Palatin sets Dec 12, 2024 annual meeting; proxy deadlines announced
Annual Meeting set for December 12, 2024; record date October 28, 2024.
-
Palatin shareholders elect all seven directors, approve equity plan share increase and say-on-pay
All seven directors elected: Carl Spana, John Prendergast, Robert deVeer, J. Stanley Hull, Alan Dunton, Arlene Morris, Anthony Manning.
-
Palatin Technologies raises ~$6.1M via warrant inducement with institutional investor
Enters inducement letter; institutional investor exercises existing warrants for $6.1M gross proceeds.
-
Palatin Q3 net loss $8.4M; Phase 3 DED study meets pain endpoint, 7 of 11 secondary endpoints
Phase 3 MELODY-1 for PL9643 in dry eye disease met co-primary pain endpoint (P<0.025) and 7 of 11 secondary endpoints at 12 weeks; rapid onset at 2 weeks.
-
Palatin Q2 FY2024 net loss $7.8M; Vyleesi sale closed; pipeline catalysts ahead
Net loss of $7.8M ($0.56/share) vs net income of $2.7M ($0.25) in Q2 FY2023.
-
Palatin closes $10M registered direct offering; details Vyleesi sale to Cosette with $12M upfront
Registered direct offering closed Feb 1: 1,831,503 shares at $5.46, gross $10M, net proceeds ~$9.2M.
-
Palatin sells Vyleesi rights to Cosette for up to $171M; $12M upfront
Up-front payment of $12M plus sales-based milestones up to $159M based on annual net sales of $15M to $200M.
-
NYSE American accepts Palatin's plan to regain listing compliance; deadline April 2025
Stockholders' equity fell below $2M (Section 1003(a)(i)) and $4M (1003(a)(ii)) due to net losses.
-
Palatin Q1 FY2024 net loss narrows to $5.9M; Vyleesi revenue up 142% YoY
Net loss per share $(0.48) vs $(0.86) YoY; Vyleesi net revenue $2.1M, +142% YoY.
-
Palatin Technologies raises $5M in registered direct offering and private placement of warrants
Sold 1,325,000 shares and pre-funded warrants for 1,033,491 shares at $2.12/unit; private warrants for 2,358,491 shares at $2.12 exercise price.
-
Palatin prelim Q1: Vyleesi gross revenue $4.6M, net $2.1M, up 100% and 137% YoY
Gross product revenue $4.6M (+11% qoq, +100% YoY); net product revenue $2.1M (+18% qoq, +137% YoY).
-
Palatin receives NYSE American non-compliance notice for insufficient stockholders' equity
Received NYSE American notice on Oct 10, 2023; stockholders' equity below $2M and $4M thresholds.
-
Palatin reports FY2023 net loss $27.5M; Vyleesi net revenue up 298%; PL9643 fully enrolled
Net loss of $27.5M ($2.53 diluted EPS) for FY2023 vs $36.2M loss ($3.79 EPS) in FY2022.
-
Palatin to present at H.C. Wainwright investment conference on Sept 13
Palatin management will present at the H.C. Wainwright 25th Annual Global Investment Conference.
-
PL9643 MELODY-1 Phase 3 study enrolled 570 patients with moderate-to-severe dry eye disease.
-
Palatin initiates Phase 2 study of bremelanotide/PDE5i combo for ED non-responders
Approximately 30–40% of ED patients do not respond to PDE5i monotherapy.
-
Palatin: Fosun reports first Vyleesi sale in China; Kwangdong completes Phase 3 enrollment
Fosun dispensed first Vyleesi prescription in Hainan Province, China.
-
Palatin partners with UpScriptHealth to expand Vyleesi access via telehealth platform
Palatin (PTN) entered strategic partnership with telemedicine company UpScriptHealth.
-
Palatin to present at Canaccord Genuity Growth Conference on Aug 9
Management to participate in Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023.
-
Palatin prelim Q4 Vyleesi net revenue $1.7M, up 122% YoY; prescriptions +89% YoY
Gross product revenue $4.1M, up 20% QoQ and 78% YoY.
-
All seven director nominees elected; broker non-votes 2,999,632 for each director.
-
PL8177 preserved podocyte count and WT1 expression in diabetic rats vs. vehicle.
-
Palatin Q3 FY2023 net loss $7.1M; Vyleesi revenue up 453% YoY; Phase 3 dry eye data positive
Net loss $7.1M ($0.63/share) vs $7.6M ($0.80) prior year; operating expenses $8.5M.
-
Palatin to report Q3 FY2023 results on May 16; conference call set for 11:00 a.m. ET
Results press release due before market open on Tuesday, May 16, 2023.
-
Palatin updates on PL9643 dry eye Phase 3 lead-in data and PL8177 UC data
PL9643 lead-in data from MELODY-1 Phase 3 shows excellent ocular tolerability and broad efficacy on dry eye signs/symptoms.
-
Palatin to host KOL webinar on PL9643 Phase 3 dry eye data on May 8, 2023
Webinar to review positive PL9643 Phase 3 MELODY-1 Lead-In population data for moderate to severe dry eye disease.
-
Palatin reports positive initial Phase 3 data for PL9643 dry eye drug at ARVO
PL9643 showed statistically significant improvement on multiple sign and symptom endpoints in Phase 2 and Phase 3 lead-in data.
-
Topically administered PL9588 reduced intraocular pressure (IOP) in normotensive rabbits.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material